Jump to comment:
No eLetters have been published for this article.
Jump to section
Related Articles
Cited By...
- Spontaneous haemorrhage in subdural hygroma in an Alzheimers patient on lecanemab
- Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities
- Brain magnetic resonance imaging software to support dementia diagnosis in routine clinical practice: a barrier to adoption study in the National Health Service (NHS) England
- Donanemab outperformed Aducanumab and Lecanemab on cognitive, but not on biomarker and safety outcomes: systematic review, frequentist and Bayesian network meta-analyses
- Teaching NeuroImage: Severe Amyloid-Related Imaging Abnormalities After Anti-{beta}-Amyloid Monoclonal Antibody Treatment
- Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know
- Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology
- Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?
- Brain Shrinkage in Anti-{beta}-Amyloid Alzheimer Trials: Neurodegeneration or Pseudoatrophy?
- CAA-ri and ARIA: Two Faces of the Same Coin?
- Reply:
- MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?